Lupin Limited

Lupin Limited

Lupin Limited has been assigned an Environmental, Social and Governance (ESG) Rating of 'Crisil ESG 69' and a Core ESG Rating of 'Crisil Core ESG 65' by Crisil ESG Ratings & Analytics Ltd.

Lupin Limited

Lupin Limited has informed the Exchange regarding Allotment of 30967 Shares under ESOP.

Lupin Limited

Lupin Limited has received an ESG rating of 60 from ESG Risk Assessments & Insights Limited, placing the company in the 'Adequate' category. The rating is based on publicly available data and was prepared independently by the rating agency.

Lupin Limited

Lupin Limited has entered into an Exclusive License Agreement with Visus Therapeutics, Inc. to commercialize YUVEZZI, a proprietary ophthalmic product, in the European Union, the United Kingdom, Switzerland, Norway, and Iceland.

Lupin Limited

Lupin Limited has informed the Exchange regarding the demise of Dr. Sofia Mumtaz, President, Legal & Compliance, Canada, ANZ & NEA Business, a Senior Management Personnel of the Company.

Lupin Limited

Lupin Limited has received final approval from the US FDA for its Abbreviated New Drug Application for Pitolisant Tablets, 4.45 mg and 17.8 mg, which are bioequivalent to Wakix for the approved indications.

Lupin Limited

Lupin Limited has announced a record quarter with total revenues from operations and EBITDA exceeding INR 8,000 crores and INR 2,400 crores, respectively, for the first time in its history. The company has also reported a 16th consecutive quarter of YoY growth.

Lupin Limited

Lupin Limited has received approval from the U.S. FDA for its Abbreviated New Drug Application for Sodium Zirconium Cyclosilicate for Oral Suspension, with estimated annual sales of USD 568 million in the U.S.

Lupin Limited

Lupin Limited has informed the Exchange about Schedule of Institutional Investors Meets.

Lupin Limited

Lupin Limited has published unaudited financial results for the quarter ended June 30, 2026, with revenue and EBITDA increasing by 82,768.9 and 20,173.6 respectively, and net profit increasing by 14,511.3.

Lupin Limited

Lupin Limited has made the audio recording of its Q1 FY27 earnings call available on its website.

Lupin Limited

Lupin Limited has released its Q1 FY27 investor presentation, highlighting strong revenue growth and healthy EBITDA margins. The company has launched several new products, including Azilsartan Medoxomil and Ranibizumab, and received approvals for its products in various markets.

Lupin Limited

Lupin Limited has released its Q1 FY27 results, showing strong revenue growth with healthy EBITDA margins. The company has launched several new products, including Azilsartan Medoxomil, Ranibizumab, and Luforbec, and has received approvals for its products in various markets, including the US and China.

Lupin Limited

Lupin Limited has announced its Q1 FY2027 results, reporting a 33.3% YoY growth in sales to INR 82,172 Mn, with EBITDA up 42.8% to INR 25,799 Mn. The company's gross margin expanded to 74.6% and PBT increased 42.5% to INR 20,174 Mn. The company received 6 ANDA approvals from the US FDA and launched 3 products in the US market.

Lupin Limited

Lupin Limited has submitted unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with revenue from operations at ₹71,719.0 crore, and net profit after tax at ₹27,146.0 crore.

Lupin Limited

Lupin Limited has informed the Exchange regarding the Proceedings of the Forty-Fourth Annual General Meeting held on August 04, 2026. The Company has submitted the Exchange a copy of consolidated Scrutinizer's report along with voting results.

Lupin Limited

Lupin Limited has received approval from the US FDA for its Abbreviated New Drug Application for Diazepam Injection USP, 10 mg/2 mL (5 mg/mL), Single-Dose Prefilled Syringes.

Lupin Limited

Lupin Limited has announced the U.S. FDA approval and launch of Sugammadex Injection, a bioequivalent to Bridion Injection of Merck, for the reversal of neuromuscular blockade in adults and pediatric patients undergoing surgery.

Lupin Limited

Lupin Limited has informed the Exchange about the schedule of their earnings call for Q1 FY27, to be held on August 07, 2026, at 16:30 hrs (IST).

Lupin Limited